Background/Aim
GUDAPATI, S. (2021). Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma. Afribary. Retrieved from https://tracking.afribary.com/works/apdworale-posterpresentationbyprathima
GUDAPATI, SRAVYA "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma" Afribary. Afribary, 25 Aug. 2021, https://tracking.afribary.com/works/apdworale-posterpresentationbyprathima. Accessed 06 Nov. 2024.
GUDAPATI, SRAVYA . "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma". Afribary, Afribary, 25 Aug. 2021. Web. 06 Nov. 2024. < https://tracking.afribary.com/works/apdworale-posterpresentationbyprathima >.
GUDAPATI, SRAVYA . "Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma" Afribary (2021). Accessed November 06, 2024. https://tracking.afribary.com/works/apdworale-posterpresentationbyprathima